Consensus on the treatment of vitiligo – Brazilian Society of Dermatology,

Detalhes bibliográficos
Autor(a) principal: Dellatorre,Gerson
Data de Publicação: 2020
Outros Autores: Antelo,Daniela Alves Pereira, Bedrikow,Roberta Buense, Cestari,Tania Ferreira, Follador,Ivonise, Ramos,Daniel Gontijo, Castro,Caio Cesar Silva de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Anais brasileiros de dermatologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962020000700070
Resumo: Abstract Background: Vitiligo is a muco-cutaneous, autoimmune, localized, or disseminated disease, which manifests through hypochromic or achromic macules, with loss in quality of life. The prevalence of vitiligo in Brazil was determined to be 0.54%. There is no on-label medication for its treatment. To date, no Brazilian consensus on the treatment of vitiligo had been written. Objectives: The objective of this group of Brazilian dermatologists with experience in the treatment of this disease was to reach a consensus on the clinical and surgical treatment of vitiligo, based on articles with the best scientific evidence. Methods: Seven dermatologists were invited, and each was assigned two treatment modalities to review. Each treatment (topical, systemic, and phototherapy) was reviewed by three experts. Two experts reviewed the surgical treatment. Subsequently, the coordinator compiled the different versions and drafted a text about each type of treatment. The new version was returned to all experts, who expressed their opinions and made suggestions for clarity. The final text was written by the coordinator and sent to all participants to prepare the final consensus. Results/Conclusion: The experts defined the following as standard treatments of vitiligo: the use of topical corticosteroids and calcineurin inhibitors for localized and unstable cases; corticosteroid minipulse in progressive generalized vitiligo; narrowband UVB phototherapy for extensive forms of the disease. Surgical modalities should be indicated for segmental and stable generalized vitiligo. Topical and systemic anti-JAK drugs are being tested, with promising results.
id SBD-1_c5335a237d938df9500b00e9e62244a0
oai_identifier_str oai:scielo:S0365-05962020000700070
network_acronym_str SBD-1
network_name_str Anais brasileiros de dermatologia (Online)
repository_id_str
spelling Consensus on the treatment of vitiligo – Brazilian Society of Dermatology,Clinical protocolsCombined modality therapyConsensusTreatment outcomeVitiligoAbstract Background: Vitiligo is a muco-cutaneous, autoimmune, localized, or disseminated disease, which manifests through hypochromic or achromic macules, with loss in quality of life. The prevalence of vitiligo in Brazil was determined to be 0.54%. There is no on-label medication for its treatment. To date, no Brazilian consensus on the treatment of vitiligo had been written. Objectives: The objective of this group of Brazilian dermatologists with experience in the treatment of this disease was to reach a consensus on the clinical and surgical treatment of vitiligo, based on articles with the best scientific evidence. Methods: Seven dermatologists were invited, and each was assigned two treatment modalities to review. Each treatment (topical, systemic, and phototherapy) was reviewed by three experts. Two experts reviewed the surgical treatment. Subsequently, the coordinator compiled the different versions and drafted a text about each type of treatment. The new version was returned to all experts, who expressed their opinions and made suggestions for clarity. The final text was written by the coordinator and sent to all participants to prepare the final consensus. Results/Conclusion: The experts defined the following as standard treatments of vitiligo: the use of topical corticosteroids and calcineurin inhibitors for localized and unstable cases; corticosteroid minipulse in progressive generalized vitiligo; narrowband UVB phototherapy for extensive forms of the disease. Surgical modalities should be indicated for segmental and stable generalized vitiligo. Topical and systemic anti-JAK drugs are being tested, with promising results.Sociedade Brasileira de Dermatologia2020-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962020000700070Anais Brasileiros de Dermatologia v.95 suppl.1 2020reponame:Anais brasileiros de dermatologia (Online)instname:Sociedade Brasileira de Dermatologia (SBD)instacron:SBD10.1016/j.abd.2020.05.007info:eu-repo/semantics/openAccessDellatorre,GersonAntelo,Daniela Alves PereiraBedrikow,Roberta BuenseCestari,Tania FerreiraFollador,IvoniseRamos,Daniel GontijoCastro,Caio Cesar Silva deeng2021-03-22T00:00:00Zoai:scielo:S0365-05962020000700070Revistahttp://www.anaisdedermatologia.org.br/https://old.scielo.br/oai/scielo-oai.phpabd@sbd.org.br||revista@sbd.org.br1806-48410365-0596opendoar:2021-03-22T00:00Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)false
dc.title.none.fl_str_mv Consensus on the treatment of vitiligo – Brazilian Society of Dermatology,
title Consensus on the treatment of vitiligo – Brazilian Society of Dermatology,
spellingShingle Consensus on the treatment of vitiligo – Brazilian Society of Dermatology,
Dellatorre,Gerson
Clinical protocols
Combined modality therapy
Consensus
Treatment outcome
Vitiligo
title_short Consensus on the treatment of vitiligo – Brazilian Society of Dermatology,
title_full Consensus on the treatment of vitiligo – Brazilian Society of Dermatology,
title_fullStr Consensus on the treatment of vitiligo – Brazilian Society of Dermatology,
title_full_unstemmed Consensus on the treatment of vitiligo – Brazilian Society of Dermatology,
title_sort Consensus on the treatment of vitiligo – Brazilian Society of Dermatology,
author Dellatorre,Gerson
author_facet Dellatorre,Gerson
Antelo,Daniela Alves Pereira
Bedrikow,Roberta Buense
Cestari,Tania Ferreira
Follador,Ivonise
Ramos,Daniel Gontijo
Castro,Caio Cesar Silva de
author_role author
author2 Antelo,Daniela Alves Pereira
Bedrikow,Roberta Buense
Cestari,Tania Ferreira
Follador,Ivonise
Ramos,Daniel Gontijo
Castro,Caio Cesar Silva de
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Dellatorre,Gerson
Antelo,Daniela Alves Pereira
Bedrikow,Roberta Buense
Cestari,Tania Ferreira
Follador,Ivonise
Ramos,Daniel Gontijo
Castro,Caio Cesar Silva de
dc.subject.por.fl_str_mv Clinical protocols
Combined modality therapy
Consensus
Treatment outcome
Vitiligo
topic Clinical protocols
Combined modality therapy
Consensus
Treatment outcome
Vitiligo
description Abstract Background: Vitiligo is a muco-cutaneous, autoimmune, localized, or disseminated disease, which manifests through hypochromic or achromic macules, with loss in quality of life. The prevalence of vitiligo in Brazil was determined to be 0.54%. There is no on-label medication for its treatment. To date, no Brazilian consensus on the treatment of vitiligo had been written. Objectives: The objective of this group of Brazilian dermatologists with experience in the treatment of this disease was to reach a consensus on the clinical and surgical treatment of vitiligo, based on articles with the best scientific evidence. Methods: Seven dermatologists were invited, and each was assigned two treatment modalities to review. Each treatment (topical, systemic, and phototherapy) was reviewed by three experts. Two experts reviewed the surgical treatment. Subsequently, the coordinator compiled the different versions and drafted a text about each type of treatment. The new version was returned to all experts, who expressed their opinions and made suggestions for clarity. The final text was written by the coordinator and sent to all participants to prepare the final consensus. Results/Conclusion: The experts defined the following as standard treatments of vitiligo: the use of topical corticosteroids and calcineurin inhibitors for localized and unstable cases; corticosteroid minipulse in progressive generalized vitiligo; narrowband UVB phototherapy for extensive forms of the disease. Surgical modalities should be indicated for segmental and stable generalized vitiligo. Topical and systemic anti-JAK drugs are being tested, with promising results.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962020000700070
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962020000700070
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.abd.2020.05.007
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
publisher.none.fl_str_mv Sociedade Brasileira de Dermatologia
dc.source.none.fl_str_mv Anais Brasileiros de Dermatologia v.95 suppl.1 2020
reponame:Anais brasileiros de dermatologia (Online)
instname:Sociedade Brasileira de Dermatologia (SBD)
instacron:SBD
instname_str Sociedade Brasileira de Dermatologia (SBD)
instacron_str SBD
institution SBD
reponame_str Anais brasileiros de dermatologia (Online)
collection Anais brasileiros de dermatologia (Online)
repository.name.fl_str_mv Anais brasileiros de dermatologia (Online) - Sociedade Brasileira de Dermatologia (SBD)
repository.mail.fl_str_mv abd@sbd.org.br||revista@sbd.org.br
_version_ 1752126424224890880